Listen
BYFAVO 20 mg (remimazolam) - Procedural sedation / general anaesthesia
Opinions on drugs -
Posted on
May 21 2024
Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement for:
- BYFAVO (remimazolam) 20 mg powder for solution for injection in adults for procedural sedation,
- BYFAVO (remimazolam) 50 mg powder for concentrate for solution for injection/infusion in adults for intravenous induction and maintenance of general anaesthesia.
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of BYFAVO (remimazolam) 20 mg powder for solution for injection is substantial in the MA indication. The Committee deems that the clinical benefit of BYFAVO 50 mg (remimazolam) powder for concentrate for solution for injection/infusion is substantial in the MA indication. |
Clinical Added Value
| no clinical added value |
BYFAVO (remimazolam) 20 mg powder for solution for injection provides no clinical added value (CAV V) in the care pathway for procedural sedation in adults. BYFAVO (remimazolam) 50 mg powder for concentrate for solution for injection/infusion provides no clinical added value (CAV V) in the care pathway for intravenous induction and maintenance of general anaesthesia in adults. |
English version
Contact Us
Évaluation des médicaments
